CRISIL upgrades rating for Ipca Laboratories’ long term bank facilities

04 Jul 2011 Evaluate

CRISIL has upgraded rating for Ipca Laboratories’ long term bank facilities from 'AA-/Positive' to 'AA/Stable' and has also reaffirmed the ratings at 'P1+' for its short term facilities i.e. Rs 1.5 billion Short Term Debt and Rs 2.2 billion Letter of Credit.

The credit rating agency has also upgraded the rating for its Rs 500 million Non-Convertible Debentures, Rs 4.3 billion Cash Credit, Rs 180 million Long-Term Loan and Rs 1,000 million Proposed Long-Term Bank Loan Facility from AA-/Positive to AA/Stable.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.

Ipca Laboratories Share Price

1397.55 -26.50 (-1.86%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×